| Product Name | NebuSelect™ Recombinant Human MMP-9, Avi-His-tag |
|---|---|
| Catalog Number | NBL-242295 |
| Alias/Synonyms | MMP-9; MMP-9; GELB; CLG4B; MANDP2; Gelatinase B |
| Appearance | see COA |
| Molecule Weight | |
| CAS | N/A |
| Solubility | Water Soluble |
| Storage | Short term 4℃; Long term -20℃. |
| Shelf Life | 2 years |
| Additional info 1 | P14780 |
| Additional info 2 |
| Catalog Numbe | Size | Price | Inventory Level | |
| NBL-242295-100ug | 100ug | Inquire | Inquire | |
| NBL-242295-1mg | 1mg | Inquire | Inquire | |
| NBL-242295-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human MMP-9, Avi-His-tag
Catalog#:
NBL-242295
Description:
NebuSelect™ Recombinant Human MMP-9, Avi-His-tag(Cat#NBL-242295) is expressed in HEK293 with His tag and Avi tag at the C-Terminus. The protein needs to be activated by APMA to have hydrolytic activity.It contains Ala20-Asp707.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 79.3 kDa. Due to glycosylation, the protein migrates to 85-100 kDa based on Bis-Tris PAGE result.
Target Name:
MMP-9; MMP-9; GELB; CLG4B; MANDP2; Gelatinase B
Target Information:
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.